Kite Pharma, a subsidiary of Gilead Sciences, is a biopharmaceutical company focused on developing cancer immunotherapy products, particularly CAR T-cell therapies. As a Gilead Company since 2017, it also makes strategic corporate venture investments in cell therapy and immuno-oncology companies such as Aspen Neuroscience and Ensoma.
60% of their portfolio is in Biotech & Life Sciences. They made 2 investments in the last 12 months. Their most common stage is series-c (60% of deals). Average disclosed round size is $88.6M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series C
Last 12 Mo
2
Team
Gallia Levy, MD, PhD
Development
Joe Spiegler
Legal
Michelle Roth
Human Resources
Sarah Stephens
Public Affairs
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Aspen Neuroscience | Series C | $115M | Nov 2025 |
 Aspen Neuroscience | Series C | $115M | Nov 2025 |
 Ensoma | Series B | $135M | May 2023 |
 Shoreline Biosciences | Series B | $43M | Apr 2021 |
 Vineti | Series C | $35M | Feb 2020 |
Top Co-Investors
Cormorant Asset Management4 shared
Lifeforce Capital3 shared
S323 shared
Axon Partners Group2 shared
OrbiMed2 shared
LYFE Capital2 shared
Revelation Partners2 shared
ARCH Venture Partners2 shared
Frazier Life Sciences2 shared
Balyasny Asset Management2 shared
Casdin Capital1 shared
Hive Ventures1 shared
Threshold Ventures1 shared
Canaan Partners1 shared
Novartis Venture Fund1 shared
Novartis Pharma AG1 shared
Cardinal Health1 shared
Avon Ventures1 shared
Bowery Capital1 shared
Struck Capital1 shared
Last updated: 7 October 2026